Catherine Schulte
Stock Analyst at Baird
(3.93)
# 584
Out of 5,163 analysts
148
Total ratings
53.17%
Success rate
9.11%
Average return
Main Sectors:
Stocks Rated by Catherine Schulte
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences | Maintains: Outperform | $26 → $28 | $18.15 | +54.27% | 2 | Feb 27, 2026 | |
| GRAL GRAIL | Maintains: Outperform | $113 → $82 | $43.06 | +90.43% | 2 | Feb 20, 2026 | |
| TEM Tempus AI | Initiates: Outperform | $59 | $49.98 | +18.05% | 1 | Feb 17, 2026 | |
| GH Guardant Health | Initiates: Outperform | $120 | $85.49 | +40.37% | 1 | Feb 17, 2026 | |
| A Agilent Technologies | Maintains: Outperform | $142 → $165 | $111.51 | +47.97% | 18 | Nov 25, 2025 | |
| EXAS Exact Sciences | Maintains: Outperform | $72 → $88 | $103.57 | -15.03% | 15 | Nov 4, 2025 | |
| AVTR Avantor | Maintains: Outperform | $15 → $17 | $7.93 | +114.38% | 14 | Oct 24, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,210 → $1,230 | $1,173.74 | +4.79% | 10 | Aug 4, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $553 → $567 | $464.37 | +22.10% | 28 | Jul 24, 2025 | |
| DHR Danaher | Maintains: Outperform | $226 → $229 | $187.32 | +22.25% | 11 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $2 | $3.08 | -35.06% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $41 | $40.60 | +0.86% | 4 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $88 → $68 | $50.85 | +33.73% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $25.56 | +48.67% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $33 | $43.28 | -23.75% | 3 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $335 → $281 | $118.94 | +136.25% | 7 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $208 → $217 | $286.57 | -24.28% | 7 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $187.85 | -89.35% | 1 | Jun 28, 2018 |
Caris Life Sciences
Feb 27, 2026
Maintains: Outperform
Price Target: $26 → $28
Current: $18.15
Upside: +54.27%
GRAIL
Feb 20, 2026
Maintains: Outperform
Price Target: $113 → $82
Current: $43.06
Upside: +90.43%
Tempus AI
Feb 17, 2026
Initiates: Outperform
Price Target: $59
Current: $49.98
Upside: +18.05%
Guardant Health
Feb 17, 2026
Initiates: Outperform
Price Target: $120
Current: $85.49
Upside: +40.37%
Agilent Technologies
Nov 25, 2025
Maintains: Outperform
Price Target: $142 → $165
Current: $111.51
Upside: +47.97%
Exact Sciences
Nov 4, 2025
Maintains: Outperform
Price Target: $72 → $88
Current: $103.57
Upside: -15.03%
Avantor
Oct 24, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $7.93
Upside: +114.38%
Mettler-Toledo International
Aug 4, 2025
Maintains: Neutral
Price Target: $1,210 → $1,230
Current: $1,173.74
Upside: +4.79%
Thermo Fisher Scientific
Jul 24, 2025
Maintains: Outperform
Price Target: $553 → $567
Current: $464.37
Upside: +22.10%
Danaher
Jul 23, 2025
Maintains: Outperform
Price Target: $226 → $229
Current: $187.32
Upside: +22.25%
May 13, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $3.08
Upside: -35.06%
Apr 21, 2025
Maintains: Neutral
Price Target: $40 → $41
Current: $40.60
Upside: +0.86%
Feb 19, 2025
Downgrades: Neutral
Price Target: $88 → $68
Current: $50.85
Upside: +33.73%
Mar 1, 2023
Maintains: Outperform
Price Target: $42 → $38
Current: $25.56
Upside: +48.67%
Nov 21, 2022
Maintains: Outperform
Price Target: $56 → $33
Current: $43.28
Upside: -23.75%
Sep 22, 2020
Maintains: Neutral
Price Target: $335 → $281
Current: $118.94
Upside: +136.25%
Oct 30, 2019
Maintains: Neutral
Price Target: $208 → $217
Current: $286.57
Upside: -24.28%
Jun 28, 2018
Maintains: Outperform
Price Target: $17 → $20
Current: $187.85
Upside: -89.35%